Aberrant expression levels and/or glycosylation modification related to abnormal biological characteristics of glycoprotein alpha-1-antichymotrypsin (AACT) have been reported in tumors, including IDC tissue, which suggests that AACT may serve as novel biomarker for tumor diagnosis and prognosis [155]. This evidence concerns the gene SERPINA3 and neoplasm.